Key points are not available for this paper at this time.
Metabolon is an emerging technology company developing proprietary analytical methods and software for biomarker discovery using metabolomics. The company's aim is to measure all small molecules (<1500 Da) in a biological sample. These small-molecule compounds include biochemicals of cellular metabolism and xenobiotics from diet and environment. Our proprietary mLIMStrade mark system contains advanced metabolomic software and automated data-processing tools that use a variety of data-analysis and quality-control algorithms to convert raw mass-spectrometry data to identified, quantitated compounds. Metabolon's primary focus is a fee-for-service business that exploits this technology for pharmaceutical and biotechnology companies, with additional clients in the consumer goods, cosmetics and agricultural industries. Fee-for-service studies are often collaborations with groups that employ a variety of technologies for biomarker discovery. Metabolon's goal is to develop technology that will automatically analyze any sample for the small-molecule components present and become a standard technology for applications in health and related sciences.
Ryals et al. (Sun,) studied this question.